These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 29305365)
1. Rash and subcutaneous fat necrosis after DEB-TACE with doxorubicin. Elsayed AG; Martin JM; Pacioles T BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29305365 [TBL] [Abstract][Full Text] [Related]
2. Supraumbilical skin rash and fat necrosis after transcatheter arterial chemoembolization: a case report. Lin CC; Wu DK; Shih PM; Liu GC; Chuang WL Kaohsiung J Med Sci; 2004 Jan; 20(1):36-40. PubMed ID: 15481565 [TBL] [Abstract][Full Text] [Related]
3. Supraumbilical subcutaneous fat necrosis after transcatheter arterial chemoembolization with drug-eluting beads: case report and review of the literature. Kim HY; Bae SH; Park CH; Song MJ; Choi JY; Yoon SK; Jung ES; Chun HJ Cardiovasc Intervent Radiol; 2013 Feb; 36(1):276-9. PubMed ID: 22382809 [No Abstract] [Full Text] [Related]
4. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777 [TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study. Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418 [TBL] [Abstract][Full Text] [Related]
6. Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol. Recchia F; Passalacqua G; Filauri P; Doddi M; Boscarato P; Candeloro G; Necozione S; Desideri G; Rea S Oncol Rep; 2012 May; 27(5):1377-83. PubMed ID: 22294036 [TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. Huang K; Zhou Q; Wang R; Cheng D; Ma Y J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059 [TBL] [Abstract][Full Text] [Related]
9. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752 [TBL] [Abstract][Full Text] [Related]
10. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737 [TBL] [Abstract][Full Text] [Related]
11. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849 [TBL] [Abstract][Full Text] [Related]
12. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802 [TBL] [Abstract][Full Text] [Related]
13. Meta-Analysis of Doxorubicin-Eluting Beads via Transcatheter Arterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma. Hui Y; Ruihua T; Jing L; Yaxiong L; Ji L; Linjie Y; Dongyan S; Mingliang J; Qingsheng H; Junling S Hepatogastroenterology; 2015 Jun; 62(140):1002-6. PubMed ID: 26902045 [TBL] [Abstract][Full Text] [Related]
14. Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. Richter G; Radeleff B; Stroszczynski C; Pereira P; Helmberger T; Barakat M; Huppert P Cardiovasc Intervent Radiol; 2018 Apr; 41(4):587-593. PubMed ID: 29167967 [TBL] [Abstract][Full Text] [Related]
15. Contrast-enhanced ultrasonography of hepatocellular carcinoma after chemoembolisation using drug-eluting beads: a pilot study focused on sustained tumor necrosis. Moschouris H; Malagari K; Papadaki MG; Kornezos I; Matsaidonis D Cardiovasc Intervent Radiol; 2010 Oct; 33(5):1022-7. PubMed ID: 20101403 [TBL] [Abstract][Full Text] [Related]
16. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS J Surg Oncol; 2010 May; 101(6):476-80. PubMed ID: 20213741 [TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile. Spreafico C; Cascella T; Facciorusso A; Sposito C; Rodolfo L; Morosi C; Civelli EM; Vaiani M; Bhoori S; Pellegrinelli A; Marchianò A; Mazzaferro V Cardiovasc Intervent Radiol; 2015 Feb; 38(1):129-34. PubMed ID: 24870698 [TBL] [Abstract][Full Text] [Related]
18. Case report: Steatonecrosis in the upper abdomen following transcatheter arterial embolization for hepatocellular carcinoma. Umemura T; Yamamura N; Nagata A; Shibata A; Yamashita K; Ohata T; Yamada T; Katsuyama T; Kiyosawa K J Gastroenterol Hepatol; 1998 May; 13(5):471-4. PubMed ID: 9641642 [TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma Supplied by Extrahepatic Collateral Arteries. Lokken RP; Fidelman N; Kolli KP; Kerlan RK J Vasc Interv Radiol; 2016 Nov; 27(11):1698-1704. PubMed ID: 27397617 [TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices. Fohlen A; Tasu JP; Kobeiter H; Bartoli JM; Pelage JP; Guiu B Diagn Interv Imaging; 2018 Sep; 99(9):527-535. PubMed ID: 29609903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]